跳至主要内容
临床试验/NCT05288686
NCT05288686进行中(未招募)不适用

Use of Superparamagnetic Iron Oxide (SPIO) Versus Conventional Radioisotope and Patent Blue Dye in Sentinel Lymph Node Detection for Breast Cancer: a Randomized Controlled Trial

The University of Hong Kong1 个研究点 分布在 1 个国家目标入组 282 人开始时间: 2018年7月24日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
282
试验地点
1
主要终点
sentinel lymph node detection rate per patient

研究概览

简要总结

Sentinel lymph node biopsy is mandatory during breast cancer operation for disease staging and treatment. The localization of sentinel lymph node is by the injection of radioisotope and blue dye, which is the gold standard. However the use of radioisotope and blue dye are associated with specific drawbacks. Superparamagnetic iron oxide is a magnetic tracer which is FDA-approved for sentinel lymph node localization. The hypothesis of this study is superparamagnetic iron oxide can replace the conventional dual mapping of radioisotope and blue dye in the detection of sentinel lymph nodes for early breast cancers.

详细描述

Sentinel lymph node biopsy has replaced axillary dissection as the standard of care in clinically node negative breast cancer. Lymphatic mapping with radioisotope and blue dye were most studied tracer agents and their combination was shown to give the highest nodal identification rate and lowest false negative rate. However the use of radioisotope is strictly monitored due to its radioactivity and blue dye is associated with potential allergic reactions and skin tattoo. Superparamagnetic iron oxide is non-radioactive. It gives an audible signal with the magnetometer and a brown color as visual cue. It has demonstrated comparable nodal identification rate with the conventional method in multiple non-inferiority trials in Europe and the USA. There was no randomized controlled trial for a head-to-head comparison between these mapping technique. The hypothesis of this study is superparamagnetic iron oxide alone can replace the conventional dual mapping of radioisotope and blue dye.

Previous literature suggested the nodal detection rate for conventional method and SPIO was around 97%. Assuming a non-inferiorly limit of 5%, with a power of 80% and 5% significance level, the number of patients per treatment arm should be 144. We will need a sample size of 300 patients, taking into account a loss to follow-up of <5%.

All patients recruited will be provided full explanation of the study and written voluntary consents will be obtained before randomization.

All data will be prospectively collected by dedicated research assistant and computerized into a database. All statistical analysis will be performed with Statistical Product and Service Solution (SPSS) version 24. Missing information will be marked and significant missing data will be excluded from analysis. Chi-square test will be used to compare discrete variables and student T test or Mann Whitney U test for continuous variables. P value less than 0.05 will be considered statistically significant.

Personal data will be obtained by principal investigator and dedicated research assistant to allow analysis of the results. These data will be anonymous, only identified by the first three letters of patient's name. The file will be encrypted and stored in the study institution. All the information will be solely for research purpose and kept strictly confidential.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

Masking is not possible due to the different color of the injected tracer.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All patients with clinical T1-3N0 invasive ductal carcinoma or invasive lobular carcinoma planned for breast conservative surgery or mastectomy, with sentinel lymph node biopsy
  • Patients planned for upfront operation or neoadjuvant chemotherapy are allowed

排除标准

  • Patients with hypersensitivity to dextran compounds, iron or blue dye
  • Patients with iron overload disease
  • Pregnant or lactating patients
  • Patients with pacemaker or other implantable metallic devices in chest wall or prosthesis in shoulder
  • Mentally incompetent patients

结局指标

主要结局

sentinel lymph node detection rate per patient

时间窗: At the time of operation

Successful sentinel lymph node localization for each arm

次要结局

  • Duration of sentinel lymph node biopsy(Duration of the operation from incision of axillary fascia to satisfactory nodal basin count)
  • Detection rate of pathologically involved sentinel lymph nodes(At operation)
  • Number of sentinel lymph nodes detected(At the time of operation)
  • Duration of skin stain(post-operative 3 month, 6 month, 12 month and 18 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

MAN Chi Mei Vivian

Honorary Clinical Assistant Professor

The University of Hong Kong

研究点 (1)

Loading locations...

相似试验

Use of Superparamagnetic Iron Oxide (SPIO) in... | 临床试验